Efficacy of Infliximab as a second Bio in patients with refractory rheumatoid arthritis

Efficacy of Infliximab as a second Bio in patients with refractory rheumatoid arthritis - Infliximab as a second Bio

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020799

Enrollment

Registered

2016-02-01

Start date

2016-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with rheumatoid arthritis treated with only one bio except for infliximab more than 3.2 in DAS28-ESR patients with

Exclusion criteria

Exclusion criteria: contraindication of infliximab and methotorexate pregnant women nursing women

Design outcomes

Primary

Measure	Time frame
DAS28	—

Countries

Japan

Contacts

Public ContactToshiyuki Bohgaki

Hokkaido University Hospital Medicine II

tbohgaki@huhp.hokudai.ac.jp011-706-5915

Outcome results